Home / Leaderboard / Bausch Health Companies Inc.
Bausch Health Companies Inc.
Thomas J. Appio · Asset Manager · Buyout
Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals International, Inc., is a global diversified pharmaceutical company headquartered in Laval, Quebec. The company traces its origins to ICN Pharmaceuticals, founded in 1959, and underwent a major transformation in 2013 with the acquisition of Bausch & Lomb. Rebranded in 2018 to signal a governance reset, the firm focuses on developing, manufacturing, and marketing a wide array of products in gastroenterology, hepatology, neurology, dermatology, and international pharmaceuticals. Known historically for an aggressive, debt-fueled acquisition strategy, Bausch Health now operates through key segments such as Salix and Solta Medical, while maintaining a significant controlling interest in the publicly traded eye-care leader Bausch + Lomb.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +17.2% |
| YTD return | +0.7% |
| Sharpe ratio | 3.80 |
| Win rate | 100% |
| AUM | $0.0B |
| Inception | Oct 1, 2025 |
| Updated | Aug 20, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $0.0B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.bauschhealth.com |
Current Holdings
Updated on Aug 20, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| BLCO | Bausch + Lomb Corp | 100.0% | +17.2% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Oct 1, 2025 | BUY | BLCO | 0.0% → 100.0% |
Investment Style Analysis
Bausch Health Companies Inc. is widely recognized for employing a Buyout strategy. As of Aug 20, 2026, the firm oversees approximately $0.0B in assets under management (AUM). The portfolio demonstrates a clear preference for the Medical Instruments & Supplies sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Oct 1, Bausch Health Companies Inc. made a significant move by increasing exposure to BLCO. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Bausch Health employs a decentralized operating model designed to drive organic growth through its core therapeutic areas while prioritizing strategic capital allocation and liability management. Historically recognized for a 'platform' investment strategy, the company focused on the acquisition of high-potential specialty pharmaceutical assets and late-stage R&D to maximize efficiency and market reach. Its current philosophy emphasizes optimizing its diverse portfolio—including gastroenterology and medical aesthetics—while executing a long-term plan to unlock shareholder value through the strategic separation of its Bausch + Lomb eye-care business and the reduction of corporate debt.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Bausch Health Companies Inc..
Similar Investment Style
Based on Buyout.
- PetSmart LLC — Ken Hicks · 3M +15.2%
- Lindsay Goldberg LLC — Robert D. Lindsay · 3M -11.3%
- Sociedad Estatal de Participaciones Industriales — María Belén Gualda González · 3M 0.0%
- Baring Vostok Capital Partners Limited — Michael Calvey · 3M +13.3%
Frequently asked questions
How is the simulated portfolio for Bausch Health Companies Inc. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Bausch Health Companies Inc.'s largest holding?
As of the latest filing, Bausch Health Companies Inc.'s top position is Bausch + Lomb Corp (BLCO), representing 100.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Bausch Health Companies Inc.'s historical performance and risk profile?
Our simulation indicates a total return of +17.2% with a win rate of 100%. Notably, the portfolio maintains a Sharpe Ratio of 3.80, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Bausch Health Companies Inc. primarily invest in?
Bausch Health Companies Inc. has a strong preference for the Medical Instruments & Supplies sector, which makes up 100.0% of their disclosed assets. The portfolio also has exposure to other industries, indicating a specific thematic focus.
Is Bausch Health Companies Inc.'s portfolio concentrated or diversified?
Bausch Health Companies Inc. runs a highly concentrated portfolio with 1 disclosed positions. The top 3 holdings alone account for 100.0% of the total portfolio weight, suggesting a strategy that favors deep research into a few key names.
How has Bausch Health Companies Inc. performed in 2026?
Our AI-simulated model portfolio for Bausch Health Companies Inc. tracks a Year-to-Date (YTD) return of +0.7%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Thomas J. Appio manage Bausch Health Companies Inc. directly?
Yes, Thomas J. Appio serves as the key portfolio manager for Bausch Health Companies Inc., overseeing the investment strategy and final capital allocation decisions.